23andMe to Report FY2024 Second Quarter Financial Results
25 oct. 2023 16h05 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
27 sept. 2023 16h05 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster...
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
14 sept. 2023 07h00 HE
|
23andMe, Inc.
23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell...
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
31 août 2023 17h28 HE
|
23andMe, Inc.
510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer Many of these...
23andMe Reports FY2024 First Quarter Financial Results
08 août 2023 16h05 HE
|
23andMe, Inc.
Reaffirmed Full Year Revenue Guidance and Raised Full Year Guidance for Net Loss and Adjusted EBITDA Deficit Webcast at 4:30 pm ET, August 8, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 08,...
23andMe to Report FY2024 First Quarter Financial Results
25 juil. 2023 16h05 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
20 juil. 2023 09h23 HE
|
23andMe, Inc.
23andMe is the first and only direct-to-consumer product to offer a suite of FDA-authorized pharmacogenetics reports, with medication insights Lipid-lowering statins are one of the most commonly...
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
21 juin 2023 07h00 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part...
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
25 mai 2023 16h05 HE
|
23andMe, Inc.
Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE...
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
16 mai 2023 07h00 HE
|
23andMe, Inc.
66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their DNA health profile 34 percent of doctors said...